MedTrace Logo

Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids

NCT02670382 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-04-14

Study results available
· View outcomes & findings →

Summary

The objective of this study is to provide critical information regarding both common and distinctive roles of EPA and DHA in systemic inflammation and lipid metabolism.

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

EPA

10 week supplementation

DIETARY_SUPPLEMENT

DHA

10 week supplementation

DIETARY_SUPPLEMENT

sunflower oil

4-week lead-in

Sponsors & Collaborators

  • Tufts University

    lead OTHER

Principal Investigators

  • Stefania Lamon-Fava, PhD · Tufts University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2020-05-31
Completion
2020-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02670382 on ClinicalTrials.gov